Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer.

Authors

Pia-Allison E Roa
Rima Bazzi, Beaumont Health

Document Type

Article

Publication Date

1-2022

Publication Title

International journal of STD & AIDS

Abstract

We present the case of a 78-year-old African American man with a history of human immunodeficiency virus diagnosed in 2007 who was newly diagnosed with pancreatic cancer. A percutaneous endoscopic gastrostomy tube was placed during the initial inpatient visit of pancreatic cancer diagnosis due to persistent dysphagia. Due to PEG placement and the patient's wish to continue his previous antiretroviral therapy, the patient crushed his fixed-dose bictegravir/emtricitabine/tenofovir alafenamide under the direction of a physician and has maintained virologic suppression.

Volume

33

Issue

1

First Page

97

Last Page

98

Recommended Citation

Roa PE, Bazzi R. Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer. Int J STD AIDS. 2022 Jan;33(1):97-98. doi: 10.1177/09564624211048702. PMID: 34787026.

DOI

10.1177/09564624211048702

ISSN

1758-1052

PubMed ID

34787026